Announcements Trials
Browse Landscape

Phase

Phase 1/2 3

Status

Unknown 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 132Recurrence 33Precursor Cell Lymphoblastic Leukemia-Lymphoma 23Neoplasms, Plasma Cell 15Neoplasms 10Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Leukemia 7Immunoglobulin Light-chain Amyloidosis 7Lymphoma, Non-Hodgkin 6Amyloidosis 6Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma 5Hematologic Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Burkitt Lymphoma 5Paraproteinemias 4Lymphoma, Mantle-Cell 4Leukemia, Myeloid, Acute 4Hematologic Diseases 4Blood Protein Disorders 4Neoplasm Metastasis 3Myelodysplastic Syndromes 3Lymphoma, B-Cell 3Lung Neoplasms 3Esophageal Neoplasms 3Corneal Diseases 3Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2

Interventions

Dexamethasone 3daratumumab 2Lenalidomide 2pomalidomide 1nirogacestat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Corneal Diseases × Dexamethasone × Clear all
NCT05280275 2023-12-01

A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible

Hellenic Society of Hematology

Phase 1/2 Unknown
36 enrolled
Plasma cell

Blood Protein Disorders, Corneal Diseases, Hematologic Diseases, Multiple Myeloma, Neoplasms, Paraproteinemias, Neoplasms, Plasma Cell

NCT05573802 2023-10-24

A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma

Hellenic Society of Hematology

Phase 1/2 Recruiting
36 enrolled
Plasma cell

Blood Protein Disorders, Corneal Diseases, Hematologic Diseases, Multiple Myeloma, Neoplasms, Paraproteinemias, Neoplasms, Plasma Cell

NCT05581875 2022-10-17

A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory

Hellenic Society of Hematology

Phase 1/2 Not yet recruiting
48 enrolled
Plasma cell

Blood Protein Disorders, Corneal Diseases, Hematologic Diseases, Multiple Myeloma, Neoplasms, Paraproteinemias, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡